Zedira

Zedira GmbH is a German biotech firm founded in 2006, pioneering the clinical validation of transglutaminases as therapeutic targets. The company's core asset is ZED1227, a first-in-class oral TG2 inhibitor that successfully completed a Phase 2a study in celiac disease and is advancing in further trials, including for non-alcoholic fatty liver disease (NAFLD). Beyond its therapeutic pipeline, Zedira is a global supplier of high-quality transglutaminase-related research reagents, serving both academia and industry, and has established key partnerships with Dr. Falk Pharma and Takeda for clinical development.

Proprietary platform for developing selective small-molecule inhibitors targeting dysregulated human transglutaminases, supported by deep enzymology expertise and a comprehensive suite of research reagents and recombinant enzymes.

In celiac disease, ZED1227 is the first and most advanced TG2 inhibitor, facing competition from other modalities like gluten-degrading enzymes (e.g., latiglutenase) and immune tolerization approaches. In NAFLD/NASH, it enters a crowded field of late-stage candidates targeting various pathways (FXR, PPAR, etc.), where demonstrating clear anti-fibrotic efficacy will be critical for differentiation.